10X Genomics（股票代码：TXG）今日盘前股价大涨7.81%，主要受益于公司发布的强劲二季度财报。
根据10X Genomics公布的财报显示，截至6月30日的第二季度，公司调整后每股收益为0.28美元，远超分析师平均预期的每股亏损0.37美元。公司营收同比增长12.9%至1.7291亿美元，同样高于市场预期的1.3943亿美元。此外，10X Genomics本季度净利润达到3454万美元，相比去年同期业绩显著改善。
这一亮眼的业绩表现引发了多家投行上调10X Genomics的目标价。巴克莱将该公司的目标价从13美元上调至15美元，摩根大通则将目标价从9美元上调至13美元。分析师普遍认为，10X Genomics在基因组学领域的创新技术和市场地位使其具有长期增长潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.